News | May 26, 2025
Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
There are 38.4 million people with diabetes in the United States
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Subscribe To Our Newsletter & Stay Updated
